Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be at least 18 years of age.~* Males and females with a documented diagnosis of UC at least 4 months prior to entry into the study.~* Subjects with moderately to severely active UC based on Mayo score criteria.~* Subjects must have failed or be intolerant of at least one of the following treatments for UC:~  * Corticosteroids (oral or intravenous).~ * Azathioprine or 6 mercaptopurine (6 MP).~ * Anti TNF therapy.~Exclusion Criteria:~* Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn's disease.~* Subjects with disease limited to distal 15 cm.~* Subjects without previous treatment for UC (ie, treatment naïve).~* Subjects displaying clinical signs of fulminant colitis or toxic megacolon.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tofacitinib 10 mg BID (Type: EXPERIMENTAL): None
- Placebo BID (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).